Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GRP safety standards will require more thorough NDA preparation by sponsors -- Wyeth's Derivan.

Executive Summary

GRP SAFETY STANDARDS WILL REQUIRE MORE THOROUGH NDA PREPARATION, WYETH-AYERST Assistant VP- Research Albert Derivan, MD, indicated at a Dec. 18 Good Review Practices Integrated Safety Review workshop. "We want to do everything that we can to ensure a speedy review and if we can prepare the documents so that it can be reviewed quickly, we're going to do that," he said. The meeting discussed an FDA guidance on integrated safety reviews ("The Pink Sheet" Dec. 9, p. 6).

Latest Headlines
See All
UsernamePublicRestriction

Register

PS029345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel